Company intelligence / Profile preview

Botalys

Ownership: Private
Employees: ~49
Development stage: Commercial

Overview

Botalys has commercialized ultra-pure botanical ingredients such as Korean ginseng and Nordic Rhodiola using proprietary indoor farming. Clinical results are not detailed publicly; products are positioned on purity/efficacy rather than clinical trial outcomes. Patent activity suggests ongoing research into medicinal uses of botanicals including opioid antagonists.

Therapeutic areas: OtherNeurology
Modalities: Botanical extractsnatural compounds
Industry: Agriculture & AgTech

Drug pipeline

2 assets

Korean ginseng extract

Commercial

Indications: Mental stamina

1 more asset in the full pipeline.

Request access →

Partnerships

Brightseed partnership to cultivate bioactive botanicals for beauty, health & wellness sectors

Beyond the preview

Go deeper on Botalys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Botalys.

Explore the full profile